King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain.
Clin Adv Hematol Oncol. 2022 Jun;20(6):384-390.
Follicular lymphoma (FL) is a heterogeneous entity with disparate outcomes based on clinical and pathologic characteristics. An increasingly detailed understanding of high-grade FL (grade 3) has led to the identification of separate categories of FL3A and FL3B. Recently, genomic studies have made much progress in delineating the genetic differences between FL3A and FL3B. Although a general consensus exists that FL3B follows an aggressive course matching that of diffuse large B-cell lymphoma, there is less certainty regarding the course of FL3A. Uncertainty also exists regarding the management of high-grade FL. Given that a majority of the prospective landmark trials in FL have excluded patients with high-grade FL, most of the available evidence is retrospective. This review summarizes the recent advances in the management of high-grade FL.
滤泡性淋巴瘤（FL）是一种异质性实体，其临床和病理特征不同，结局也不同。人们对高级别 FL（3 级）的认识不断加深，已确定了 FL3A 和 FL3B 的不同类别。最近，基因组研究在阐明 FL3A 和 FL3B 之间的遗传差异方面取得了很大进展。尽管人们普遍认为 FL3B 具有与弥漫性大 B 细胞淋巴瘤相匹配的侵袭性病程，但对于 FL3A 的病程尚不确定。对于高级别 FL 的治疗管理也存在不确定性。鉴于 FL 的大多数前瞻性标志性试验都排除了高级别 FL 患者，因此大多数可用证据都是回顾性的。这篇综述总结了高级别 FL 治疗管理的最新进展。
